Lesions classified as intermediate by histopathological characteristics and melanomas in situ harbor a broader spectrum of oncogenic alterations, including BRAFV600K or BRAFK601E, NRAS, GNAQ or GNA11, and TERTprom mutations, showing genetic differences between benign and malignant neoplasms. The gene discussed is NRAS; the disease is cancer.